CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells

Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a new promising target for the treatment of ovarian cancer. Our previous study showed that cross‐reacting material 197 (CRM197), a specific HB‐EGF inhibitor, significantly reverses resistance against paclitaxel in paclitaxel‐resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiao‐han, Li, Hui, Zheng, Xiu‐shuang, Lu, Mei‐song, An, Yuan, Zhang, Xiao‐lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797568/
https://www.ncbi.nlm.nih.gov/pubmed/31490008
http://dx.doi.org/10.1002/cam4.2512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797568/
https://www.ncbi.nlm.nih.gov/pubmed/31490008
http://dx.doi.org/10.1002/cam4.2512

Ejemplares similares